Tenovix

Composition

Combipack contains 3 vials & 3 ampoules. 

Each vial contains: tenoxicam BP 20 mg

Each ampoule contains: sterile water for injection BP 2 ml

Indications for use

Tenovix should be used with the following indications:

• For the relief of pain and inflammation in osteoarthritis and rheumatoid arthritis;
• For the short term management of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.
• For the management of postoperative pain.

IV, IM Tenovix  can be used for these indications in those patients considered unable to take oral Tenovix.

Mode of application

Adults:

Tenovix  should be given IV or IM. A single daily dose of 20 mg for one to two days initially to be continued with the oral form, with administration at the same time each day. The lyophilisate should be dissolved in 2 ml of sterile water for injections and the reconstituted solution should be used immediately.

Higher doses should be avoided as they do not usually achieve significantly greater therapeutic effect but may be associated with a higher risk of adverse events. In acute musculoskeletal disorders treatment should not normally be required for more than 7 days, but in severe cases it may be continued up to a maximum of 14 days.

Use in the elderly:

As with other non-steroidal anti-inflammatory drugs, Tenovix  should be used with special caution in elderly patients. The elderly are at increased risk of serious adverse reactions. They are also more likely to be receiving concomitant medication or to have impaired hepatic, renal or cardiovascular function. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for GI bleeding during NSAID therapy.

Children:

There are insufficient data to make a recommendation for administration of Tenovix  to children.

Use in renal and hepatic insufficiency:

Creatinine clearance -Greater than 25 mL/min.  Dosage regimen -Usual dosage but monitor patients carefully.  Creatinine clearance – Less than 25 mL/min  Dosage regimen – Insufficient data to make dosage recommendations.

Because of the high plasma protein-binding of tenoxicam, caution is required when plasma albumin concentrations are markedly reduced (e.g. in nephrotic syndrome) or when bilirubin concentrations are high.

There is insufficient information to make dosage recommendations for Tenovix  in patients with pre-existing hepatic impairment.